Acura Beneish M Score

ACUR
 Stock
  

USD 0.05  0.00  0.00%   

This module uses fundamental data of Acura Pharma to approximate the value of its Beneish M Score. Acura Pharma M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please continue to Acura Pharma Piotroski F Score and Acura Pharma Altman Z Score analysis.
  
As of 11/28/2022, Total Debt is likely to grow to about 5.7 M. Also, Debt Current is likely to grow to about 7.6 M. Acura Pharma Total Assets Per Share are relatively stable at the moment as compared to the past year. Acura Pharma reported last year Total Assets Per Share of 0.80. As of 11/28/2022, Quick Ratio is likely to grow to 4.89, while Return on Investment is likely to drop (73.34) .
At this time, it appears that Acura Pharma Cmn is an unlikely manipulator. The earnings manipulation may begin if Acura Pharma's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Acura Pharma executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Acura Pharma's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.05
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables0.87Focus
Asset Quality1.15Focus
Expense Coverage1.25Focus
Gross Margin Strengs0.86Focus
Accruals Factor1.25Focus
Depreciation Resistance0.93Focus
Net Sales Growth1.23Focus
Financial Leverage Condition0.93Focus

Acura Pharma Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Acura Pharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Selling General and Administrative Expense3.5 M2.3 M
Way Up
Decreasing
Slightly volatile
Revenues6.3 M5.1 M
Fairly Up
Decreasing
Very volatile
Trade and Non Trade Receivables778 K721 K
Significantly Up
Increasing
Slightly volatile
Property Plant and Equipment Net573.8 K435.6 K
Significantly Up
Decreasing
Slightly volatile
Operating Income(8.1 M)(7.5 M)
Significantly Down
Decreasing
Very volatile
Net Cash Flow from Operations(6.9 M)(6.4 M)
Significantly Down
Decreasing
Stable
Liabilities Non Current97 K94.5 K
Fairly Up
Decreasing
Very volatile
Current Liabilities2.5 M3.1 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities5.8 M6.3 M
Significantly Down
Increasing
Slightly volatile
Investments Current11 M9.8 M
Moderately Up
Decreasing
Slightly volatile
Investments11 M9.8 M
Moderately Up
Decreasing
Slightly volatile
Gross Margin69.8880.91
Fairly Down
Increasing
Slightly volatile
Depreciation Amortization and Accretion209.9 K143.8 K
Way Up
Increasing
Stable
Debt Non Current97 K94.5 K
Fairly Up
Decreasing
Slightly volatile
Debt Current7.6 M7.1 M
Significantly Up
Increasing
Slightly volatile
Total Debt5.7 M5.6 M
Slightly Up
Decreasing
Slightly volatile
Assets Non Current514.5 K501.3 K
Fairly Up
Decreasing
Stable
Current AssetsM6.8 M
Fairly Up
Decreasing
Slightly volatile
Total Assets9.7 M9.4 M
Fairly Up
Decreasing
Slightly volatile

Acura Pharma Cmn Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Acura Pharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Acura Pharma in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Acura Pharma's degree of accounting gimmicks and manipulations.

About Acura Pharma Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

209,916

Acura Pharma Depreciation Amortization and Accretion is relatively stable at the moment as compared to the past year. Acura Pharma reported last year Depreciation Amortization and Accretion of 143,750

Acura Pharma Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Acura Pharma. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201720182019202020212022 (projected)
Assets Non Current2.04 M1.69 M1.38 M557 K501.3 K514.49 K
Total Debt2.69 M4.22 M6 M6.27 M5.64 M5.68 M
Debt Current2.32 M2.38 M2.69 M6.16 M7.09 M7.65 M

About Acura Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Acura Pharma Cmn's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acura Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acura Pharma Cmn based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acura Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acura Pharma's short interest history, or implied volatility extrapolated from Acura Pharma options trading.

Pair Trading with Acura Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acura Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acura Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acura Pharma

+0.72WFCWells Fargo Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to Acura Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acura Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acura Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acura Pharma Cmn to buy it.
The correlation of Acura Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acura Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acura Pharma Cmn moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acura Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Acura Pharma Piotroski F Score and Acura Pharma Altman Z Score analysis. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for analysis

When running Acura Pharma Cmn price analysis, check to measure Acura Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acura Pharma is operating at the current time. Most of Acura Pharma's value examination focuses on studying past and present price action to predict the probability of Acura Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acura Pharma's price. Additionally, you may evaluate how the addition of Acura Pharma to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Please note, there is a significant difference between Acura Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Acura Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acura Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.